Investigational drug · Phase 3
BMS-986365
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "BMS-986365"
First trial start
2025
Mar 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986365", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986365" as an intervention, largest first.
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT06764485 · 960 participants (planned) · Start Mar 13, 2025 · Primary completion Sep 12, 2027
Drug: BMS-986365; Enzalutamide and 3 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Birmingham, Alabama; Gilbert, Arizona; Anaheim, California · 227 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT04428788 · 131 participants · Start Jun 22, 2020 · Primary completion Oct 28, 2025
Drug: CC-94676; CC1083611 and 1 more · For: Prostatic Neoplasms
Sites: Stanford, California; Washington D.C., District of Columbia; Sarasota, Florida · 19 sites in all
- Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male ParticipantsPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT06417229 · 102 participants · Start May 28, 2024 · Primary completion Feb 19, 2025
Drug: BMS-986365; Rabeprazole · For: Healthy Participants
Sites: Lenexa, Kansas
CelgeneBristol Myers Squibb (BMY)
NCT06433505 · 24 participants · Start May 30, 2024 · Primary completion Feb 14, 2025
Drug: BMS-986365; [14C] BMS-986365 and 2 more · For: Healthy Volunteers
Sites: Madison, Wisconsin
CelgeneBristol Myers Squibb (BMY)
NCT07242781 · 22 participants · Start Dec 15, 2025 · Primary completion Apr 9, 2026
Drug: BMS-986365; Itraconazole and 1 more · For: Healthy Volunteers
Sites: Miami, Florida
- A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07335796 · 7 participants · Start Jan 9, 2026 · Primary completion Jan 9, 2030
Drug: BMS-986165; Degarelix · For: Prostate Cancer
Sites: Basking Ridge, New Jersey; Montvale, New Jersey; Commack, New York · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Rathkopf DE, Patel MR, Choudhury AD, et al. · Ann Oncol 2026
- Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365.
Mortensen DS, Nayak S, Plantevin-Krenitsky V, et al. · J Med Chem 2026
- Can PROTACs truly become oral drugs?
Alhafi A, Gupta V · Drug Discov Today 2026
- Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.
Nayak S, Norris JD, Ammirante M, et al. · Clin Cancer Res 2026
- rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.
Chi KN, McKay RR, Sandhu S, et al. · Future Oncol 2025
- Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Rathkopf DE, Patel MR, Choudhury AD, et al. · Ann Oncol 2025
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- DeutenzalutamidePhase 31 trial
AstraZeneca · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.